Please try another search
DiNonA Inc., a biopharmaceutical development company, researches, develops, and commercializes antibody related therapeutics and diagnostic reagents. Its pipeline products include DNP0007 that is in pre-clinical phase to treat immune suppression and rhenoid; DNP002, a product candidate that is in Phase I clinical trials to treat colon and stomach cancer; DNP005 and PD-1 to treat cancer; DNP019/COVID19 to treat SARS-CoV-2 infection; DNP004 that is in pre-clinical phase for the treatment of breast cancer; and DNP001 for the treatment of actue leukemia and cancer. The company offers monoclonal antibodies to treat hepatitis B virus, hepatocarcinoma, diabetes, superbacteria MRSA, myocardial infraction, and cancer. The company was founded in 1999 and is headquartered in Seoul, South Korea. DiNonA Inc. is subsidiary of Kumho HT, Inc.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review